Delayed Methotrexate Clearance in Interim Maintenance
Priya is 11 years old with B-ALL in interim maintenance. She received high-dose methotrexate 5 g/m2 over 24 hours, and the infusion completed 42 hours ago. Protocol requires leucovorin until the methotrexate level is below 0.1 micromol/L. Current data: methotrexate level 8.6 micromol/L, creatinine 0.9 mg/dL (baseline 0.4), urine pH 6.4, urine output 1.0 mL/kg/hr, BUN 22. She has grade 1 oral mucositis, is drinking poorly, and her mother reports giving two doses of ibuprofen at home for a headache. Her next scheduled leucovorin dose is 15 mg/m2 IV every 6 hours.
1. Interpret the methotrexate level and identify what is driving it.
Read the worked answer
At 42 hours after a 24-hour high-dose infusion, the expected methotrexate level should already be well under 1 micromol/L. A level of 8.6 micromol/L is markedly delayed clearance, not a borderline result.
Methotrexate is cleared renally and is a weak acid that precipitates in acidic urine. Three preventable drivers are visible in this scenario:
- Acidic urine (pH 6.4) -- at this pH, methotrexate and its metabolite crystalize in the tubules, causing the nephrotoxicity that then causes the high level, which causes more nephrotoxicity. This is a self-amplifying loop.
- Poor oral intake plus a rising creatinine (0.4 to 0.9) -- she is underhydrated and already has acute kidney injury.
- Ibuprofen -- NSAIDs reduce renal prostaglandin-mediated perfusion and compete for tubular secretion, worsening methotrexate accumulation and toxicity.
The rising creatinine is the mechanism, the level is the consequence, and the mucositis is the early clinical signal that toxicity is already happening. Expect myelosuppression and hepatotoxicity to follow in the next several days.
2. What orders and nursing actions do you anticipate in the next few hours?
Read the worked answer
Escalate the leucovorin immediately. Do not give the protocol's 15 mg/m2 dose. With a level this far above the expected curve, the rescue dose is typically increased substantially (for example to 100 mg/m2 IV every 6 hours, per protocol and pharmacy guidance) and continued until the level is below 0.1 micromol/L. Leucovorin is time-critical: the longer high systemic levels persist, the more rescue is needed.
Alkalinize and hydrate. Urine pH target is generally at least 7.0 (many protocols 7.0-8.0). This means IV sodium bicarbonate per protocol and a structured hydration rate ordered by the team, with strict intake and output, daily weights, and bladder emptying -- you cannot alkalinize urine you are not making.
Stop the ibuprofen and screen for other nephrotoxins (contrast, other NSAIDs, trimethoprim, proton pump inhibitors where relevant). Document this in the medication record so it does not recur at home.
Monitoring: serum creatinine, electrolytes, LFTs, and CBC at least daily (more often if worsening); methotrexate level per protocol; daily mucositis assessment using a consistent scale; skin assessment for erythema and desquamation.
Care priorities that nurses own: mouth care every 2-4 hours with a soft brush and alcohol-free rinse, pain control, nutrition support before she becomes unable to swallow, and teaching the family why the "hydration and bicarbonate" part of the regimen is treatment and not optional.
3. Under what circumstances would glucarpidase be considered, and what must you remember if it is given?
Read the worked answer
Glucarpidase is a rescue enzyme that rapidly cleaves methotrexate into inactive metabolites. It is reserved for methotrexate levels far above the expected curve with developing renal toxicity or clinical toxicity, for example a level above 1 micromol/L with rising creatinine, or the high-level thresholds specified in institutional and protocol guidance. Timing matters: it is most useful before methotrexate has distributed into tissues and caused established injury. The decision belongs to the treating oncologist with pharmacy input -- the nursing role is to flag the level and creatinine early enough that the window is not missed.
If it is given, four things must be remembered:
- Keep giving leucovorin. Glucarpidase also inactivates leucovorin, so leucovorin rescue must continue (typically for about 48 hours after the dose) to protect tissues from methotrexate still in the intracellular space.
- Separate the two drugs -- leucovorin should not be given within roughly 2 hours of glucarpidase; sequence them per pharmacy instructions.
- Do not trust the immunoassay. Standard methotrexate immunoassays cross-react with glucarpidase metabolites and will report falsely high levels; a chromatographic (HPLC) method is required to measure true levels.
- It does not cross the blood-brain barrier. Intrathecal or CNS methotrexate exposure is unaffected, so neurologic monitoring continues independently.
Simultaneously, do not lose sight of supportive care: leucovorin, alkalinization, hydration, and anticipating severe mucositis and neutropenia in the days ahead regardless of whether glucarpidase is used.